Semaglutide Reduced Exercise Motivation in Mice by Altering Brain Dopamine Signaling

Animal study using lean and diet-induced obese mice. Voluntary wheel running was measured to assess activity levels. Motivation was tested using a progressive ratio task where mice pressed a lever with increasing effort requirements to access a running wheel. Real-time dopamine dynamics in the nucleus accumbens were measured using fiber photometry during running bouts.

One of the biggest concerns about GLP-1 weight loss drugs is whether they cause muscle loss, and exercise is the primary tool patients use to counteract this. If semaglutide directly reduces exercise motivation through dopamine pathways — independent of its appetite effects — that's a clinically important finding. It could help explain why some patients on these drugs report reduced drive to exercise and has implications for how weight loss is maintained.

This study adds to a growing body of research suggesting GLP-1 drugs affect the brain's reward system beyond just food. Other studies have found reduced alcohol consumption, gambling urges, and compulsive behaviors in GLP-1 drug users. The dopamine mechanism identified here could be the common thread — and it raises important questions about whether these broad motivational effects are beneficial (reducing addictions) or harmful (reducing healthy exercise motivation).

Mouse study — dopamine dynamics and exercise motivation may not directly translate to human behavior. The study used a preprint server (bioRxiv), meaning it hasn't completed peer review. Wheel running is an innate rodent behavior that may not perfectly model human exercise motivation. The doses and pharmacokinetics of semaglutide in mice differ from human use.